Control of retinal cell fate specification by the MIR9-2 disease gene locus
Active Project Grant Awarded Last action
- Award ID
- F31EY035932
- Recipient
-
Seattle Children's Hospital UEI SZ32VTCXM799
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $176,782
Award facts
- Assistance listing
- 93.867 Vision Research
- Completion date 69% complete
- Place of performance
- Seattle, WA 98101, USA
Award details come from USAspending.gov.
Description
- Abstract
- The development of a functional central nervous system is dependent upon the proper specification of distinct cell fates by multipotent progenitor cells. While the role of protein-coding genes in this process is well studied, there is a pressing need to understand how non-coding elements, such as micrornas (MIRNAS) and enhancers, contribute to cell fate decisions as a growing number of studies implicate non-coding genomic elements in disease. The long term goal of this project is to elucidate how the microrna, MIR9-2 regulates the timing of cell fate specification during retinal development. MIR9-2, along with its distal enhancer, has been linked to retinal disease and associated phenotypes, and disruption of MIR9-2, through deletion of its enhancer, can delay the emergence of late-born cell classes. Therefore, the hypothesis of this proposal is that MIR9-2, in coordination with its enhancer, regulates specific target transcripts in progenitor cells to control the timing of neurogenesis during retinal development. Here, using in vivo mouse models, single-cell sequencing, and machine-learning directed enhancer bashing approaches, this proposal will dissect the functional role of MIR9-2 and its enhancer to understand the regulatory role they play in proper specification of retinal cell classes. The proposed research is significant, because IT will provide a comprehensive understanding of the enhancer-MIR9-2 regulatory unit and the gene networks, cell classes, and retinal structures under its control. This will further provide an opportunity to model the mechanisms of action by which non-coding elements influence the development and diseases of the central nervous system and may lead to gene targets and pathways with therapeutic potential.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $45,308 | |
| Amendment | $44,732 | |
| Amendment | $1,594 | |
| Amendment | $0 | |
| Amendment | $42,574 | |
| Original award | $42,574 |
Quick answers
Who received award F31EY035932?
F31EY035932 was awarded to Seattle Children's Hospital by National Eye Institute (National Institutes of Health) on March 1, 2025.
How much is award F31EY035932 worth?
$176,782 has been obligated on F31EY035932.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award